For research use only. Not for therapeutic Use.
Cabazitaxel (Cat No.:I002372) is a semi-synthetic taxane chemotherapy agent that belongs to the class of microtubule-targeting drugs. It acts by inhibiting microtubule depolymerization and promoting microtubule assembly, resulting in the disruption of cellular processes such as mitosis and cell division. Cabazitaxel is primarily used in the treatment of metastatic castration-resistant prostate cancer (mCRPC) that has progressed after docetaxel-based chemotherapy. It is administered intravenously and has shown improved overall survival and progression-free survival in clinical trials. Cabazitaxel offers an important therapeutic option for patients with advanced prostate cancer who have limited treatment alternatives.
| Catalog Number | I002372 |
| CAS Number | 183133-96-2 |
| Molecular Formula | C45H57NO14 |
| Purity | ≥95% |
| Target | Microtubule/Tubulin |
| Solubility | 10 mM in DMSO |
| Storage | 3 years -20C powder |
| IUPAC Name | [(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-acetyloxy-1-hydroxy-15-[(2R,3S)-2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoyl]oxy-9,12-dimethoxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate |
| InChI | InChI=1S/C45H57NO14/c1-24-28(57-39(51)33(48)32(26-17-13-11-14-18-26)46-40(52)60-41(3,4)5)22-45(53)37(58-38(50)27-19-15-12-16-20-27)35-43(8,36(49)34(55-10)31(24)42(45,6)7)29(54-9)21-30-44(35,23-56-30)59-25(2)47/h11-20,28-30,32-35,37,48,53H,21-23H2,1-10H3,(H,46,52)/t28-,29-,30+,32-,33+,34+,35-,37-,43+,44-,45+/m0/s1 |
| InChIKey | BMQGVNUXMIRLCK-OAGWZNDDSA-N |
| SMILES | CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)OC)C)OC |
| Reference | 1: Pal SK, Twardowski P, Sartor O. Critical appraisal of cabazitaxel in the <br> <br> 4: Galsky MD, Dritselis A, Kirkpatrick P, Oh WK. Cabazitaxel. Nat Rev Drug |
